Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis

…, SC Vilbrun, K Walsh, J Westenhouse, WW Yew… - The Lancet, 2018 - thelancet.com
Background Treatment outcomes for multidrug-resistant tuberculosis remain poor. We aimed
to estimate the association of treatment success and death with the use of individual drugs, …

Antituberculosis drugs and hepatotoxicity

WW Yew, CC Leung - Respirology, 2006 - Wiley Online Library
Isoniazid, pyrazinamide and rifampicin have hepatotoxic potential, and can lead to such
reactions during antituberculosis chemotherapy. Most of the hepatotoxic reactions are dose‐…

[HTML][HTML] Update on pulmonary disease due to non-tuberculous mycobacteria

JE Stout, WJ Koh, WW Yew - International Journal of Infectious Diseases, 2016 - Elsevier
Non-tuberculous mycobacteria (NTM) are emerging worldwide as significant causes of chronic
pulmonary infection, posing a number of challenges for both clinicians and researchers. …

[HTML][HTML] Multidrug resistant pulmonary tuberculosis treatment regimens and patient outcomes: an individual patient data meta-analysis of 9,153 patients

…, MH Vargas, P Viiklepp, J Westenhouse, WW Yew… - 2012 - journals.plos.org
Background Treatment of multidrug resistant tuberculosis (MDR-TB) is lengthy, toxic,
expensive, and has generally poor outcomes. We undertook an individual patient data meta-…

Management of patients with multidrug-resistant/extensively drug-resistant tuberculosis in Europe: a TBNET consensus statement

…, D Wagner, MJ Van Der Werf, B Williams, WW Yew… - 2014 - Eur Respiratory Soc
The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis
(TB) substantially challenges TB control, especially in the European Region of the World …

Antituberculosis drug-related liver dysfunction in chronic hepatitis B infection

WM Wong, PC Wu, MF Yuen, CC Cheng, WW Yew… - Hepatology, 2000 - journals.lww.com
Liver toxicity is a common side effect of antituberculosis (anti-TB) drugs. We studied the
differences in liver dysfunction observed during anti-TB treatment between hepatitis B virus …

Global lung health: the colliding epidemics of tuberculosis, tobacco smoking, HIV and COPD

RN van Zyl Smit, M Pai, WW Yew… - European respiratory …, 2010 - Eur Respiratory Soc
Tuberculosis (TB), smoking, HIV and chronic obstructive pulmonary disease (COPD) are
burgeoning epidemics in developing countries. The link between TB and HIV is well established…

Outcomes of patients with multidrug-resistant pulmonary tuberculosis treated with ofloxacin/levofloxacin-containing regimens

WW Yew, CK Chan, CH Chau, CM Tam, CC Leung… - Chest, 2000 - Elsevier
Objective To analyze outcomes of patients with multidrug-resistant tuberculosis (MDR-TB)
treated with ofloxacin/levofloxacin-containing regimens. Materials and methods From …

Targeting persisters for tuberculosis control

Y Zhang, WW Yew, MR Barer - Antimicrobial agents and …, 2012 - Am Soc Microbiol
Mycobacterial persisters, the survivors from antibiotic exposure, necessitate the lengthy
treatment of tuberculosis (TB) and pose a significant challenge for our control of the disease. We …

Mutations outside the rifampicin resistance-determining region associated with rifampicin resistance in Mycobacterium tuberculosis

…, TCK Lau, RWT Lau, PL Ho, WW Yew… - Journal of …, 2011 - academic.oup.com
Objectives Ninety-six percent of rifampicin resistance in Mycobacterium tuberculosis was
shown to be associated with mutations inside the 81 bp rifampicin resistance-determining …